Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority ...

Seven other digital technologies - Beat Better, Datos Health, Get Ready, Luscii vitals, Pumping Marvellous Cardiac Rehab Platform, R Plus Health and Sword Move - require more research before they can ...

There is not enough evidence to determine whether price variation is justified between different transcatheter heart valves for transcatheter aortic valve implantation (TAVI) in adults with aortic ...

Ten transcatheter heart valves were available on the NHS Supply Chain and included in this assessment at the time of publication. All of them had valid CE certification as class 3 implantable devices.

In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

Women, older people and Black people less likely to receive an SGLT-2 inhibitor prescription for type 2 diabetes ...

Status: Awaiting development Technology type: Medicine Decision: Selected Reason for decision: Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the ...

Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [TSID12226] Awaiting development GID-TA11821 Expected publication date: TBC ...

NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.